Claims
- 1. A .DELTA..sup.7 -prostaglandin E represented by the following formula ##STR19## wherein R.sup.11 represents a hydrogen atom, an alkyl group having 1 to 10 carbon atoms or a tri(C.sub.1-7 hydrocarbon) silyl group, R.sup.2 represents an alkyl group having 1 to 10 carbon atoms or a 5- or 6-membered cycloalkyl group wherein the alkyl group or cycloalkyl group for R.sup.2 is unsubstituted or substituted with a lower alkyl group, a lower alkoxy group, a cycloalkyl group, ethenyl, phenyl, phenoxy, trifluorophenyl or trifluoromethyl, R.sup.3 represents a hydrogen atom or a methyl group, R.sup.41 and R.sup.51 are identical or different and each represents a hydrogen atom or a protective group for the hydroxyl group, and A represents the group --CH.sub.2 CH.sub.2 --, --CH.dbd.CH-- or --C.tbd.C--, wherein the protective group for the hydroxyl group is a tri(C.sub.1-7 hydrocarbon)silyl group or a group capable of forming an acetal linkage with the oxygen atom of the hydroxyl group.
- 2. The .DELTA..sup.7 -prostaglandin E of claim 1 which is represented by the following formula ##STR20## wherein R.sup.11, R.sup.2, R.sup.3, R.sup.41, R.sup.51 and A are as defined.
- 3. The .DELTA..sup.7 -prostaglandin E of claim 1 which is represented by the following formula ##STR21## wherein R.sup.11, R.sup.2, R.sup.3, R.sup.41, R.sup.51 and A are as defined.
- 4. The .DELTA..sup.7 -prostaglandin E of any one of claims 1 to 3 wherein when R.sup.2 is said alkyl group or substituted alkyl group, the alkyl group has 5 to 8 carbon atoms.
- 5. The .DELTA..sup.7 -prostaglandin E of any one of claims 1 to 3 wherein R.sup.11 represents a hydrogen atom, a methyl group or an ethyl group
- 6. The .DELTA..sup.7 -prostaglandin E of claim 1 which is represented by the following formula ##STR22## wherein R.sup.2, R.sup.3 and A are as defined, and R.sup.13 represents a hydrogen atom, a methyl group or an ethyl group.
- 7. The .DELTA..sup.7 -prostaglandin E of claim 1 wherein the tri(C.sub.1-7 hydrocarbon)silyl group is a tri(C.sub.1 -C.sub.4 alkyl)silyl group, a diphenyl (C.sub.1 -C.sub.4)silyl group or a tribenzylsilyl group.
- 8. The .DELTA..sup.7 -prostaglandin E of claim 1 wherein the protective group capable of forming an acetal linkage with the oxygen atom of the hydroxyl group is a compound selected from the group consisting of methoxyethyl, 1-ethoxyethyl, 2-methoxy-2-propyl, 2-ethoxy-2-propyl, (2-methoxyethoxy)methyl, benzyloxymethyl, 2-tetrahydropyranyl, 2-tetrahydrofuranyl, and 6,6-dimethyl-3-oxa-2-oxo-bicyclo [3.1.0] hex-4-yl groups.
- 9. The .DELTA..sup.7 -prostaglandin E of claim 1 which is a .DELTA..sup.7 -prostaglandin E.sub.1.
- 10. The .DELTA..sup.7 -prostaglandin E of claim 9 which is selected from the group consisting of .DELTA..sup.7 -PGE.sub.1, .DELTA..sup.7 -16-methyl PGE.sub.1, .DELTA..sup.7 -16,16-dimethyl PGE.sub.1, .DELTA..sup.7 -20-methyl PGE.sub.1, .DELTA..sup.7 -17,20-dimethyl PGE.sub.1, .DELTA..sup.7 -16,17,18,19,20-pentanor-15-cyclopentyl PGE.sub.1, .DELTA..sup.7 -16,17,18,19,20-pentanor-15-cyclohexyl PGE.sub.1, .DELTA..sup.7 -15-methyl PGE.sub.1, .DELTA..sup.7 -17,17,20-trimethyl PGE.sub.1, and .DELTA..sup.7 -17,18,19,20-tetranor-16-cyclohexyl PGE.sub.1.
- 11. The .DELTA..sup.7 -prostaglandin E of claim 1 which is a .DELTA..sup.7 -prostaglandin E.sub.2.
- 12. The .DELTA..sup.7 -prostaglandin E of claim 11 which is selected from the group consisting of .DELTA..sup.7 -PGE.sub.2, .DELTA..sup.7 -16-methyl PGE.sub.2, .DELTA..sup.7 -16,16-dimethyl PGE.sub.2, .DELTA..sup.7 -20-methyl PGE.sub.2, .DELTA..sup.7 -17,20-dimethyl PGE.sub.2, .DELTA..sup.7 -16,17,18,19,20-pentanor-15-cyclopentyl PGE.sub.2, .DELTA..sup.7 -16,17,18,19,20-pentanor-15-cyclohexyl PGE.sub.2, .DELTA..sup.7 -15-methyl PGE.sub.2, .DELTA..sup.7 -17,17,20-trimethyl PGE.sub.2, .DELTA..sup.7 -17,18,19,20-tetranor-16-cyclohexyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-16-methyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-16,16-dimethyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-20-methyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-17,20-dimethyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-16,17,18,19,20-pentanor-15-cyclopentyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-16,17,18,19,20-pentanor-15-cyclohexyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-15-methyl PGE.sub.2 , .DELTA..sup.7 -5,6-dehydro-17,17,20-trimethyl PGE.sub.2, .DELTA..sup.7 -5,6-dehydro-18-oxa PGE.sub.2, and .DELTA..sup.7 -5,6-dehydro-17,18,19,20-tetranor-16-cyclopentyl PGE.sub.2.
Priority Claims (3)
Number |
Date |
Country |
Kind |
56-180954 |
Nov 1981 |
JPX |
|
56-193721 |
Dec 1981 |
JPX |
|
56-195590 |
Dec 1981 |
JPX |
|
Parent Case Info
This application is division of application Ser. No. 438,379, filed Nov. 1, 1982, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3435053 |
Real |
Mar 1969 |
|
Non-Patent Literature Citations (3)
Entry |
Fiereu et al, Reagents for Organic Synthesis p. 1183 (1969). |
House, Modern Synthetic Reacton p. 173 (1972). |
Suzuki et al, Tet Letters. 23 (39) 4057 (1982). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
438379 |
Nov 1982 |
|